HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Window Of Opportunity Opened Narrowly For Continued Use Of NAC As Dietary Ingredient In US

FDA Doesn’t Wave A White Flag, But Offers Cautionary Call For Comments

Executive Summary

FDA will “determine if rulemaking to make NAC lawful as a dietary supplement is appropriate.” Agency issued tentative responses to Council for Responsible Nutrition and Natural Products Association’s petitions asking for halt to warnings and other enforcement against firms marketing supplements containing NAC.

You may also be interested in...



AHPA Offers Hard Copy Supporting NAC's Use In Dietary Supplements Pre-DSHEA

American Herbal Products Association submits comments to on CRN and NPA petitions encouraging FDA to grant an industry request to issue a regulation finding NAC is a lawful dietary ingredient.

Comments On Petition As Good As Public Hearing On NAC’s Use As Dietary Ingredient – US FDA

Agency "does not believe a hearing is necessary at this time given the other mechanisms at stakeholders’ disposal to interact with FDA on this issue, including submission of comments" for citizen petition CRN submitted on NAC, Andrew Tantillo, acting associate commissioner for legislative affairs, tells Sen. Mike Lee.

NAC’s Future In US As Dietary Ingredient Should Have Public Hearing, Senator Urges FDA

Utah Republican Mike Lee suggests attention to N-acetyl-L-cysteine as dietary ingredient FDA has shown for overhauls of its supplement industry regulation, Rx-to-OTC switch process and OTC monograph drug program as well as for cannabinoids and its NDI notification requirement.

Related Content

Topics

UsernamePublicRestriction

Register

RS151980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel